Comprehensive Analysis of the Prognostic Values of the TRIM Family in Hepatocellular Carcinoma

被引:27
|
作者
Dai, Weiyu [1 ]
Wang, Jing [2 ]
Wang, Zhi [1 ]
Xiao, Yizhi [1 ]
Li, Jiaying [1 ]
Hong, Linjie [1 ]
Pei, Miaomiao [1 ]
Zhang, Jieming [1 ]
Yang, Ping [1 ]
Wu, Xiaosheng [1 ]
Tang, Weimei [1 ]
Jiang, Xiaoling [1 ]
Jiang, Ping [1 ]
Xiang, Li [3 ]
Li, Aimin [1 ]
Lin, Jianjiao [3 ]
Liu, Side [1 ,3 ]
Wang, Jide [1 ,3 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China
[2] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China
[3] Longgang Dist Peoples Hosp, Dept Gastroenterol, Shenzhen, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; TRIM family; signature; prognosis; LASSO; POOR-PROGNOSIS; MESENCHYMAL TRANSITION; PROMOTES; CANCER; DEGRADATION; PROGRESSION; GENE; ENCYCLOPEDIA; CONTRIBUTES; EXPRESSION;
D O I
10.3389/fonc.2021.767644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Accumulating studies have demonstrated the abnormal expressions and prognostic values of certain members of the tripartite motif (TRIM) family in diverse cancers. However, comprehensive prognostic values of the TRIM family in hepatocellular carcinoma (HCC) are yet to be clearly defined. Methods: The prognostic values of the TRIM family were evaluated by survival analysis and univariate Cox regression analysis based on gene expression data and clinical data of HCC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The expression profiles, protein-protein interaction among the TRIM family, prediction of transcription factors (TFs) or miRNAs, genetic alterations, correlations with the hallmarks of cancer and immune infiltrates, and pathway enrichment analysis were explored by multiple public databases. Further, a TRIM family gene-based signature for predicting overall survival (OS) in HCC was built by using the least absolute shrinkage and selection operator (LASSO) regression. TCGA-Liver Hepatocellular Carcinoma (LIHC) cohort was used as the training set, and GSE76427 was used for external validation. Time-dependent receiver operating characteristic (ROC) and survival analysis were used to estimate the signature. Finally, a nomogram combining the TRIM family risk score and clinical parameters was established. Results: High expressions of TRIM family members including TRIM3, TRIM5, MID1, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, and TRIM72 were significantly associated with HCC patients' poor OS. A novel TRIM family gene-based signature (including TRIM5, MID1, TRIM21, TRIM32, TRIM44, and TRIM47) was built for OS prediction in HCC. ROC curves suggested the signature's good performance in OS prediction. HCC patients in the high-risk group had poorer OS than the low-risk patients based on the signature. A nomogram integrating the TRIM family risk score, age, and TNM stage was established. The ROC curves suggested that the signature presented better discrimination than the similar model without the TRIM family risk score. Conclusion: Our study identified the potential application values of the TRIM family for outcome prediction in HCC.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma
    Jin, Zhipeng
    Sun, Dongxu
    Song, Mengying
    Zhu, Wenjing
    Liu, Huayuan
    Wang, Jianping
    Shi, Guangjun
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [32] Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma
    Huo, Junyu
    Cai, Jinzhen
    Wu, Liqun
    CANCER MEDICINE, 2023, 12 (01): : 898 - 912
  • [33] Exploration of Prognostic Biomarkers among Replication Factor C Family in the Hepatocellular Carcinoma
    Deng, Jianxiong
    Zhong, Fangyan
    Gu, Weiguo
    Qiu, Feng
    EVOLUTIONARY BIOINFORMATICS, 2021, 17
  • [34] H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma
    Zhang, Mi
    Zhao, Wei
    Liu, Shanshan
    Liu, Haichuan
    Liu, Liang
    Peng, Qiling
    Du, Chengyou
    Jiang, Ning
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2021, 14 : 1331 - 1345
  • [35] Comprehensive analysis of ASB3 as a prognostic biomarker in hepatocellular carcinoma
    Qin, Zhongqiang
    Zhu, Fangquan
    Xie, Bo
    Zhang, Yang
    Yuan, Mu
    Yang, Peipei
    Zhang, Lan
    Wei, Jianzhu
    Zhu, Ziyi
    Qian, Zhen
    Wang, Zhaoying
    Fan, Longfei
    Xu, Shuaishuai
    Tan, Yulin
    Qian, Jingyu
    TRANSLATIONAL ONCOLOGY, 2024, 39
  • [36] HMGA2 as a prognostic and immune biomarker in hepatocellular carcinoma: Comprehensive analysis of the HMG family and experiments validation
    Zhong, Qiangqiang
    Zhao, Baokang
    She, Xiao
    Liu, Xiangjie
    PLOS ONE, 2024, 19 (11):
  • [37] Mining Prognostic Biomarkers of Hepatocellular Carcinoma Based on Immune-Associated Genes
    Chen, Wenbiao
    Tang, Donge
    Ou, Minglin
    Dai, Yong
    DNA AND CELL BIOLOGY, 2020, 39 (04) : 499 - 512
  • [38] Meta-Analysis of the Prognostic and Diagnostic Significance of Serum/Plasma Osteopontin in Hepatocellular Carcinoma
    Cheng, JiWen
    Wang, WanLi
    Sun, CaiHong
    Li, MuXing
    Wang, Bo
    Lv, Yi
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2014, 48 (09) : 806 - 814
  • [39] Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity
    Zhang, Dengyong
    Liu, Sihua
    Wu, Qiong
    Ma, Yang
    Zhou, Shuo
    Liu, Zhong
    Sun, Wanliang
    Lu, Zheng
    FRONTIERS IN MEDICINE, 2023, 10
  • [40] Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma
    Jing, Qiangan
    Yuan, Chen
    Zhou, Chaoting
    Jin, Weidong
    Wang, Aiwei
    Wu, Yanfang
    Shang, Wenzhong
    Zhang, Guibing
    Ke, Xia
    Du, Jing
    Li, Yanchun
    Shao, Fangchun
    CANCER CELL INTERNATIONAL, 2023, 23 (01)